Supplementary Figure 1 from Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution

PDF file - 55K</p

Supplementary Figure Legend 1 from Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution

PDF file - 60K</p

Supplementary Table 1 from Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution

PDF file - 75K</p

Supplementary Figure 1 from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

PDF file - 35K</p

CCR Translation for This Article from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

CCR Translation for This Article from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinom

Supplementary Figure Legends from Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

PDF file - 58K</p

supplemental figure from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Supplementary Figure 1. Progression-free survival (PFS) overall (A), by UGT1A1 genotype (B), and by irinotecan dose (C).</p

Supplemental Table from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Supplementary Table 1. Toxicities during the first cycle of FOLFIRI plus bevacizumab. Number of patients (%) is indicated. Toxicities were included if they occurred in at least 10% of patients or if they were grade 3 or greater, and if they were at least possibly related to treatment.</p

Supplementary Methods from Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Supplementary Methods from Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitid

Supplementary Table 1 from Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Adverse Events.</p